Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
AssigneeImmuDyne, Inc.
InventorsNino Sorgente, Harald L. Guenther, Hannelore E. Guenther, Arun K. Bahl
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmuDyne, Inc.
InventorsNino Sorgente, Harald L. Guenther, Hannelore E. Guenther, Arun K. Bahl
Estimating the term…
The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.
A method of treating a condition associated with low bone mass in a mammal comprising administering to said mammal a water-soluble or water-insoluble beta glucan, or a pharmaceutically acceptable salt of the beta glucan, in an amount effective to inhibit bone resorption, wherein the effective amount is less than about 10 nanograms.
A method for promoting bone growth in a mammal comprising administering to said mammal a beta glucan, or a pharmaceutically acceptable salt of the beta glucan, in an amount effective to promote bone formation, wherein the effective amount is less than about 10 nanograms.
Dependencies are inferred from the claim text.